Optibrium receives further investment from Kester Capital

Optibrium™, a developer of software for drug discovery, today announced it has secured further investment from existing investors Kester Capital, a leading UK mid-market private equity firm. Funding will further drive company expansion and commercial growth of its AI-enabled drug discovery technology.

Global Biologics Consulting Services Market is poised to witness a CAGR of >15%, driven by the growing biopharmaceutical market

The biologics consulting services market is driven by increasing R&D in advanced therapies like cell & gene therapies, growing biologics regulatory approvals and significant VC fundings for biologics segment.

ChargePoint Technology’s new facility expands into Europe

Single Use Bioprocess System Market is expected to exhibit a CAGR of close to 20% over the forecast period 2020 – 2030

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Biopharma PEG Provides Monodisperse PEGs In Drug Development

The team of Biopharma PEG Scientific Inc. owns the most qualified and talented synthetic and medicinal chemists. We can provide a wide range of high purity monodispersed PEG products of multi functionalized groups in milligram to hundreds of kilograms or greater with GMP standard manufacturing capability.

Huateng Pharma Supplies Pemetrexed Intermeidates Against NSCLC

Pemetrexed is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC). It is also being studied in the treatment of other types of cancer.

BioAgilytix Appoints Euan Menzies as Chairman and Chief Executive Officer

BioAgilytix Labs, LLC (“BioAgilytix”), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, today announces the appointment, effective immediately, of Euan Menzies as Chairman and CEO. Jim Datin is retiring from his executive management role but will continue to serve as a non-executive member of the Board of Directors.

Terracon Appoint Quality Engineering Manager to Facilitate Growth and Continued Customer Satisfaction

New awards celebrate innovation in sustainable pharmaceutical packaging, winners announced at Connect in Pharma

YewMaker and Connect in Pharma announce today that the winners of the new Sustainable Medicines Packaging Awards will be announced at an in-person champagne ceremony at the Connect In Pharma event in Geneva on 14 September 2022. The new awards, run by sustainable healthcare pioneers YewMaker, will showcase and celebrate sustainable innovations revolutionising pharmaceutical packaging, with Gold, Silver and Bronze award winners under two categories.

Alfa Chemistry Releases Chemical Fluorophores for Bioanalysis, Environmental Monitoring, Clinical Diagnosis and Fluorescence Staining

Earlier this month, the management of Alfa Chemistry announced the launch of varieties of chemical fluorophores for researchers worldwide. Those newly released fluorophores, including BODIPY fluorophores, cyanine fluorophores, rhodamine fluorophores, and fluorescein fluorophores, can be widely used for bioanalysis, environmental monitoring, clinical diagnosis, fluorescence staining, as well as other application scenarios.

C. elegans Lysis/DNA Extraction Kits Available at Creative Biogene

Creative Biogene recently developed the C. elegans lysis/DNA extraction kits (CDC-k108) are now available to worldwide clients and partners.

Obtaining High-yield and Bioactive B. subtilis Bioproducts with Creative Biogene’s Cultivation Support

Creative Biogene announced the release of Bacillus subtilis cultivation service using flexible fermentation and cultivation strategies to help customers in obtaining high-yield and bioactive B. subtilis bioproducts.

MOBILION EXPANDS APPLICATIONS FOR MOBIE AND HIGHLIGHTS NEW RESEARCH AT ASMS 2022

MOBILion Systems Inc. delivers technical presentations and unveils new applications areas for its HRIM instrument, MOBIE, at ASMS 2022.

mdgroup appoints LaQuinta Jernigan as Chief Operating Officer

mdgroup appoints LaQuinta Jernigan as Chief Operating Officer Executive leadership appointment to drive seamless client experiences in patient- servicing and digitally enabled clinical trials

Andaman7 argues case for greater patient mediated research at HIMSS European Health Conference 2022

Medical Wellness Market report projects revenue to surpass US$ 4.3 Tn and CAGR would be 14.1% by 2031-end

As per Persistence Market Research’s latest industry analysis, the global medical wellness market was valued at over US$ 1 Tn in 2020, and is expected to exhibit a CAGR of 14.1% over the forecast period (2021-2031).

Terumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmic

Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has launched a pre-fillable polymer syringe for low dose applications such as ophthalmic drugs.

mdgroup recognised as one of the UK's fastest-growing private companies

mdgroup recognised as one of the UK's fastest-growing private companies 9 June 2022 - Bracknell, UK: mdgroup has been shortlisted as one of the UK's fastest-growing private companies in the inaugural Sunday Times 100 ranking.

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer

Optibrium expands UK head office with new facilities on Cambridge Innovation Park

CAMBRIDGE, UK, 08 June 2022: Optibrium™, a developer of software for drug discovery, today announced the expansion of its UK headquarters with a move to larger office premises on Cambridge Innovation Park North. The new facilities accommodate Optibrium's accelerated growth and ongoing recruitment efforts to support the continued success and development of the company's innovative technology focused on improving the efficiency and productivity of the drug discovery process.